A Study to Evaluate the Safety and Use of Human Rhinovirus in Healthy and Asthmatic Participants (MK-0000-218)

Inclusion Criteria

• •Parts 1 and 2:
• •have a Body Mass Index (BMI) between =\< 35 kg/m\^2 and \> 17 kg/m\^2
• •female of childbearing potential is not pregnant and agrees to use 2 acceptable methods of birth control until 10 days after the last visit,; or female is of non-childbearing potential
• •is a non-smoker, or has not smoked within prior 12 months, with a history of =\< 10 pack-years
• •Part 1:
• •Either of the following:
• •healthy (may have out-of season seasonal allergies)
• •mild to moderate-asthmatic with a history of spontaneous or exertional wheezing; and with all of the following for \> 4 weeks prior: daytime symptoms twice weekly or less, no activity limitation, no nocturnal symptoms, uses reliever treatment twice daily or less, with an unchanged asthma medication dose, and uses inhaled corticosteroid (ICS) at a stable dose-equivalent of =\< 500 mcg/day fluticasone propionate
• •Part 2:
• •mild to moderate-asthmatics only with a history of spontaneous or exertional wheezing; and with all of the following for \> 4 weeks prior: daytime symptoms twice weekly or less, no activity limitation, no nocturnal symptoms, uses reliever treatment twice daily or less, with an unchanged asthma medication dose, and uses ICS at a stable dose-equivalent of =\< 500 mcg/day fluticasone propionate
• •had a mild change in symptoms associated with viral syndrome, leading to temporarily increased short acting beta agonist use or increased ICS dose within the past 5 years